Can we estimate the risk of chemotherapy toxicity in Indian Geriatric patient population and utility of CRASH (Chemotherapy risk assessment scale f...

Date 24 November 2018
Event ESMO Asia 2018 Congress
Session Poster display - Cocktail
Topics Supportive Measures
Geriatric Oncology
Complications/Toxicities of Treatment
Presenter Aditi Mittal
Citation Annals of Oncology (2018) 29 (suppl_9): ix129-ix138. 10.1093/annonc/mdy444
Authors A. Mittal1, A. Agarwal2, R.R. Rangaraju3, S. Batra4, C. Gouda D2, S. Qureshi2
  • 1Hematooncology And Bmt, BLK Super Speciality Hospital, 110008 - Delhi/IN
  • 2Medical Oncology, BLK Super Speciality Hospital, 110008 - Delhi/IN
  • 3Medical Oncology, MAX Super Speciality Hospital, 110088 - Delhi/IN
  • 4Medical Oncology, MAX Super Speciality Hospital, 110017 - Delhi/IN

Abstract

Background

Aging is heterogeneous and elderly population is diverse in health status and functional reserve. Cancer is a disease of aging, with the majority falling in age group above 65 years. The management of cancer in older aged person has many facets.The standard oncology evaluation cannot recognize those with likelihood of toxicity due to treatment. We need objective and measurable factors for decision making. This study was undertaken to predict severe chemotherapy toxicity using CRASH (the Chemotherapy Risk Assessment Scale for High-Age Patients) score.

Methods

The study was conducted in the Department of Medical Oncology at Dr. B. L. Kapur Hospital, Pusa Road, New Delhi. It was a prospective observational cohort study conducted from October 2014-2016 including 100 patients. Patients with age ≥ 65 years with malignancy who were planned to be treated with a new course of cytotoxic chemotherapy were enrolled. The study commenced upon obtaining the necessary clearance from the hospital ethics. CRASH score was calculated and patient stratified in 4 categories i.e low (0-3), Int (intermediate) -low (4-6), Int-high (7-9) and high (greater than 9). Toxicity was graded as per CTCAE Adverse events criteria Version 4.0. Patients developing Grade 3/4/5 non-hematologic or grade 4/5 hematologic toxicity was taken as development of severe toxicity.Table: 448P

1.Chemotherapy risk (chemotox score)0-0.44 (score 0)
0.45-0.57(score 1)
>0.57 (score 2)
2.Hematologic risk factors and scoring1) Diastolic blood pressure (greater than 72 mm Hg = 1)
2) IADL (less than 26 = 1)
3) LDH (greater than 459 = 2)
3.Non-hematologic risk factors and scoring1) ECOG PS (1-2 = 1; 3-4 = 2)
2) MMSE (less than 30 = 2)
3) MNA (less than 28 = 2)

Heme score : Chemotox score + Hematologic risk factor Non-heme score: Chemotoix score + non-hematologic risk factor

Results

Out of 100 patients, 64 (64%) were able to complete their prescribed treatment. Three fourth of the patients had ECOG PS less or equal to 2 (76 out of 100). Forty-four percent patients (44 patients) of our study cohort experienced Grade 4 hematologic (H) or Grade 3/4 non-hematologic toxicity (NH). Highest score in each category (Heme/non-heme/CRASH) predicts nearly 100% toxicity risk. At a critical value of CRASH ≥ 6.5, the sensitivity is calculated as 100% while specificity is 89.09%. The accuracy of prediction is 93.88%. The median time taken to develop toxicity was 39.5 days.

Conclusions

CRASH score utilizes clinical assessment and basic laboratory values. Yet it accurately predicts severe chemotherapy toxicity above a critical value of 6.5. Based on above study, first 30 days are crucial as 45% of patients experienced toxicity in this time frame. With the help of these clinical predictive markers, care of elderly will be optimized.

Editorial acknowledgement

Clinical trial identification

Legal entity responsible for the study

Dr Aditi Mittal.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.